Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Por:
Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D and Labrador J
Publicada:
1 ene 2026
Ahead of Print:
13 oct 2025
Resumen:
PURPOSE: Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in patients with relapsed/refractory FLT3-ITD-negative AML. The phase III QuANTUM-First trial showed that quizartinib significantly prolonged survival versus placebo when added to standard chemotherapy, followed by single-agent maintenance, in patients with newly diagnosed (ND) FLT3-ITD-positive AML. We investigated the safety and efficacy of quizartinib in patients with ND FLT3-ITD-negative AML. METHODS: The phase II, randomized, double-blind, placebo-controlled QUIWI trial enrolled patients age 18-70 years with ND FLT3-ITD-negative (mutant-to-WT allelic ratio <0.03) AML. Patients were randomly assigned 2:1 to receive standard induction and consolidation chemotherapy combined with either quizartinib 60 mg once daily or placebo, followed by single-agent maintenance with quizartinib or placebo. The primary end point was event-free survival (EFS). Secondary end points included overall survival (OS) and safety. RESULTS: Overall, 273 patients were randomly assigned to quizartinib (n = 180) or placebo (n = 93). At data cutoff, median EFS was 20.4 months and 9.9 months in the quizartinib and placebo arms, respectively (P = .046). Median OS was not reached and 29.3 months in the quizartinib and placebo arms, respectively (P = .012); 3-year OS rates were 60.8% and 45.7%. The most frequently reported adverse events (any grade) were fever, rash, diarrhea, and mucositis. CONCLUSION: The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND FLT3-ITD-negative AML.
Filiaciones:
Montesinos P:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Rodríguez-Veiga R:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Bergua JM:
Hospital San Pedro de Alcántara, Cáceres, Spain
Algarra Algarra JL:
Hospital General de Albacete, Albacete, Spain
Botella C:
Hospital General Universitario de Alicante, Alicante, Spain
Rodríguez-Arbolí E:
Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
Bernal T:
Instituto de Investigación Sanitaria del Principado de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain
Tormo M:
Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain
Calbacho M:
Hospital Universitario 12 de Octubre, Madrid, Spain
Salamero O:
University Hospital Vall d'Hebron, and Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Serrano J:
Hospital Universitario Reina Sofia, IMIBIC, UCO, Córdoba, Spain
Noriega V:
Hospital Universitario de A Coruña, A Coruña, Spain
López-López JA:
Hospital Universitario de Jaén, Jaén, Spain
:
ICO-Hospital Germans Trias i Pujol-ICO, Institut de Recerca Josep Carreras, Badalona, Spain
López-Lorenzo JL:
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Colorado M:
Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Vidriales MB:
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
García Boyero R:
Hospital General Universitario de Castellón, Castellón de la Plana, Spain
Olave MT:
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Herrera Puente P:
Hospital Universitario Ramón y Cajal, Madrid, Spain
Arce O:
Hospital Universitario Basurto, Bilbao, Spain
Barrios M:
Hospital Universitario Regional de Málaga, Málaga, Spain
Jose Sayas M:
Hospital Universitario Doctor Peset, Valencia, Spain
Polo M:
Hospital Clínico San Carlos, Madrid, Spain
Gómez-Roncero MI:
Hospital General Universitario de Toledo, Toledo, Spain
Barragán E:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Ayala R:
Hospital Universitario 12 de Octubre, Madrid, Spain
Chillón C:
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
Calasanz MJ:
Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain
Paiva B:
Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain
Boluda B:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Casas-Avilés I:
Hospital San Pedro de Alcántara, Cáceres, Spain
Lloret-Madrid P:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Sánchez MJ:
Hospital Universitario Lucus Augusti, Lugo, Spain
Rodríguez-Medina C:
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
Cuevas L:
Hospital Universitario Araba-Txagorritxu, Araba, Spain
Raposo-Puglia JÁ:
Hospital Universitario Puerta del Mar, Cádiz, Spain
Mateos MC:
Hospital Universitario de Navarra, Navarra, Spain
Olivares M:
Hospital Galdakao-Usansolo Ospitalea, Bizkaia, Spain
Martínez-Chamorro C:
Hospital Universitario Quirónsalud Madrid and European University of Madrid, Madrid, Spain
Alonso N:
University Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, Spain
Suárez S:
Complejo Hospitalario Universitario de Vigo, Vigo, Spain
Sánchez-Vadillo I:
Hospital Universitario La Paz, Madrid, Spain
Solé Rodríguez M:
Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
González BJ:
Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Martínez-Francés A:
Hospital General Universitario Santa Lucía, Murcia, Spain
Cuello R:
Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Fernández A:
Hospital Universitario Virgen de la Victoria, Málaga, Spain
Martínez-Cuadrón D:
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Labrador J:
Hospital Universitario de Burgos, Burgos, Spain
Green Submitted, hybrid
|